0001209191-20-051996.txt : 20200924
0001209191-20-051996.hdr.sgml : 20200924
20200924191253
ACCESSION NUMBER: 0001209191-20-051996
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200924
FILED AS OF DATE: 20200924
DATE AS OF CHANGE: 20200924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heyman Richard A.
CENTRAL INDEX KEY: 0001584759
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39539
FILM NUMBER: 201196450
MAIL ADDRESS:
STREET 1: 5871 OBERLIN DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001699382
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463218129
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 642-6664
MAIL ADDRESS:
STREET 1: 8 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-24
0
0001699382
PMV Pharmaceuticals, Inc.
PMVP
0001584759
Heyman Richard A.
C/O PMV PHARMACEUTICALS, INC.
8 CLARKE DRIVE, SUITE 3
CRANBURY
NJ
08512
1
0
0
0
Stock Option (right to buy)
2.95
2027-08-16
Common Stock
11901
D
Stock Option (right to buy)
2.95
2027-08-16
Common Stock
17851
I
See footnote
Stock Option (right to buy)
2.95
2027-08-16
Common Stock
8926
I
See footnote
Stock Option (right to buy)
2.95
2027-08-16
Common Stock
8926
I
See footnote
Stock Option (right to buy)
4.22
2030-06-22
Common Stock
142714
D
Stock Option (right to buy)
4.22
2030-06-22
Common Stock
4196
I
See footnote
Stock Option (right to buy)
4.22
2030-06-22
Common Stock
2099
I
See footnote
Stock Option (right to buy)
4.22
2030-06-22
Common Stock
2099
I
See footnote
Stock Option (right to buy)
4.22
2030-06-22
Common Stock
45332
D
The shares subject to the option are subject to an early exercise provision and are immediately exercisable. One forty-eighth of the shares subject to the option vested on September 17, 2017, and an additional one forty-eighth of the shares subject to the option shall vest each month thereafter. The Reporting Person transferred all of the vested options as of September 2, 2020 to (i) Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020, (ii) Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 and (iii) Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016, and the remaining options held by the Reporting Person continue to vest according to the terms of the option grant.
All of the shares subject to the option are vested and immediately exercisable.
The stock option grants are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family.
The stock option grants are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants.
The stock option grants are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants.
One thirty-sixth of the shares subject to the option vested on July 23, 2020, and an additional one thirty-sixth of the shares subject to the option shall vest each month thereafter. The option shall vest in full and become immediately exercisable if the Reporting Person is terminated without cause or upon a change in control. The Reporting Person transferred all of the vested options as of September 2, 2020 to (i) Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020, (ii) Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 and (iii) Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016, and the remaining options held by the Reporting Person continue to vest according to the terms of the option grant.
The shares subject to the option shall vest upon the date of (a) the closing of the Issuer's initial public offering which results in at least $100,000,000 in gross proceeds with a price per share equal to at least the lowest price per share in the range on the cover of the preliminary prospectus statement utilized on the road show in connection with such initial public offering and (b) Reporting Person being a contributing factor to the closing of such initial public offering, as determined solely by the Issuer's board of directors.
/s/ David H. Mack, attorney-in-fact
2020-09-24
EX-24.3_938633
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of PMV Pharmaceuticals, Inc.
(the "Company"), hereby constitutes and appoints David H. Mack, Ph.D. and
Winston Kung, and each of them, as the undersigned's true and lawful
attorney-in-fact to:
1. prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain EDGAR codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934 or any rule or regulation of the SEC;
2. complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorney-in-fact shall in his discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigned's ownership,
acquisition or disposition of securities of the Company; and
3. do all acts necessary in order to file such forms with the SEC, any
securities exchange or national association, the Company and such other person
or agency as the attorneys-in-fact shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 24th day of September, 2020.
Signature: /s/ Richard A. Heyman
Print Name: Richard A. Heyman